RT Book, Section
A1 O’Donnell, Max R.
A1 Reddy, Divya
A1 Saukkonen, Jussi J.
A2 Kasper, Dennis L.
A2 Fauci, Anthony S.
SR Print(0)
ID 1141409799
T1 ANTIMYCOBACTERIAL AGENTS
T2 Harrison's Infectious Diseases, 3e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259835971
LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1141409799
RD 2024/04/19
AB Agents  used  for  the  treatment  of  mycobacterial  infections,  including  tuberculosis  (TB),  leprosy,  and  infections  due  to  nontuberculous  mycobacteria  (NTM),  are  administered  in  multiple-drug  regimens  for  prolonged  courses.  Currently,  more  than  160  species  of  mycobacteria  have  been  identified,  the  majority  of  which  do  not  cause  disease  in  humans.  While  the  incidence  of  disease  caused  by  Mycobacterium  tuberculosis  has  been  declining  in  the  United  States,  TB  remains  a  leading  cause  of  morbidity  and  mortality  in  developing  countries—particularly  in  sub-Saharan  Africa,  where  the  HIV  epidemic  rages.  Effective  drug  regimens  are  not  all  that  is  needed;  without  a  well-organized  infrastructure  for  diagnosis  and  treatment  of  TB,  therapeutic  and  control  efforts  are  severely  hampered.  Infections  with  NTM  have  gained  in  clinical  prominence  in  the  United  States  and  other  developed  countries.  These  largely  environmental  organisms  often  establish  infection  in  immunocompromised  patients  or  in  persons  with  structural  lung  disease.